PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 241830

Dissolution studies with a multichannel continuous-flow apparatus.

C Cakiryildiz·P J Mehta·W Rahmen·D Schoenleber
View original source ↗Export metadata ↓

Abstract

A multichannel continuous-flow apparatus for dissolution rate measurements is described. Typical data are presented to demonstrate its utility for studies with bulk drug powders as well as with tablets and capsules without any change of setup. Procedures are given for the preparation of powder samples for dissolution studies and for a simple method of changing pH for "retard" tablets. The precision in dissolution rates obtained with this apparatus and method is 1-10% mean RSD. The advantages of the method are flexibility, reproducibility, and ability to obtain data in integral or differential form.

Explore related subjects

CapsulesHydrogen-Ion ConcentrationMethodsNicotinic AcidsParticle SizePowdersSolubilityTabletsTechnology, PharmaceuticalTime FactorsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C Cakiryildiz, P J Mehta, W Rahmen, D Schoenleber. 1975. Dissolution studies with a multichannel continuous-flow apparatus.. https://doi.org/10.1002/jps.2600641024

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

Effects of sotalol on the signal-averaged electrocardiogram in patients with sustained ventricular tachycardia: relation to suppression of inducibility and changes in tachycardia cycle length.

OBJECTIVES: This study examines the effects of sotalol on the signal-averaged electrocardiogram (ECG) in patients with spontaneous and inducible sustained ventricular tachycardia and correlates these findings with the effect of sotalol on tachycardia inducibility and tachycardia rate. BACKGROUND: Standard electrocardiography generally does not detect any change in the duration of the QRS complex resulting from sotalol therapy. However, the signal-averaged ECG is more sensitive than the standard ECG for detecting changes in QRS duration induced by antiarrhythmic drugs and can also detect changes in late potential duration. METHODS: Signal-averaged electrocardiography was performed before therapy in 30 patients with spontaneous and inducible ventricular tachycardia, and both electrophysiologic study and a signal-averaged ECG were repeated during therapy with d,l-sotalol. RESULTS: During sotalol therapy the signal-averaged QRS duration decreased by 2.6 +/- 6.6 ms in the 11 patients with no inducible tachycardia during therapy, whereas it increased by 3.8 +/- 5.8 ms (p = 0.01) in the 19 patients with inducible tachycardia during therapy. In the latter group there was a significant positive correlation between prolongation of tachycardia cycle length and prolongation of late potential duration by sotalol (r = 0.56, p = 0.01). CONCLUSIONS: Sotalol can alter QRS and late potential duration as measured by the signal-averaged ECG. Prolongation of QRS duration or late potential duration may reflect a slowing of conduction by sotalol that may interfere with this agent's antiarrhythmic efficacy and slow ventricular tachycardia.

Capsules↗